title: Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
abstract: Early prediction of therapeutic outcome is important in determining whether the ongoing therapy is beneficial. In addition to anatomical response determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, recent studies have indicated that change in tumor glucose use on or after treatment correlates with histopathologic tumor regression and patient outcomes. This Perspective discusses the use of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) for pharmacodynamic evaluation in a very early phase of treatment to predict clinical outcomes in patients with advanced non-small-cell lung cancer. We conducted a study to assess whether early metabolic response determined using FDG-PET correlated with clinical outcomes in patients treated with gefitinib or those treated with carboplatin plus paclitaxel (CP). Early metabolic response to gefitinib, but not CP, correlated with the late metabolic response, anatomical response, progression-free survival, and even overall survival. A rapid effect of molecular targeted agents might not be aptly evaluated using the conventional criteria, eg, RECIST, in a very early phase of treatment before volumetric shrinkage of the tumor. Based on the findings of several studies, and on the findings from our study, use of FDG-PET might enable prediction of clinical outcomes at a very early stage of treatment, especially in patients treated with molecular targeted agents with rapid clinical efficacy.
authors: Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan.
authors: Masaki
authors: M
authors: Kanazu
authors: Nuclear Medicine and PET Center, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
authors: Kaoru
authors: K
authors: Maruyama
authors: Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Aichi, Japan.
authors: Masahiko
authors: M
authors: Ando
authors: Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan.
authors: Kazuhiro
authors: K
authors: Asami
authors: Department of Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
authors: Mari
authors: M
authors: Ishii
authors: Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan.
authors: Kazutaka
authors: K
authors: Uehira
authors: Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan.
authors: Shojiro
authors: S
authors: Minomo
authors: Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan.
authors: Yoshinobu
authors: Y
authors: Matsuda
authors: Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan.
authors: Tomoya
authors: T
authors: Kawaguchi
authors: Department of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan.
authors: Shinji
authors: S
authors: Atagi
authors: Health Examination Center, Hanwa Daini Senboku Hospital, Sakai, Osaka, Japan.
authors: Yoji
authors: Y
authors: Ogawa
authors: Health Examination Center, Hanwa Daini Senboku Hospital, Sakai, Osaka, Japan.
authors: Yoko
authors: Y
authors: Kusunoki
authors: Division of Respiratory Medicine, Koyo Hospital, Wakayama, Wakayama, Japan.
authors: Minoru
authors: M
authors: Takada
authors: Division of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan. Electronic address: kuboa@aichi-med-u.ac.jp.
authors: Akihito
authors: A
authors: Kubo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D017239:Paclitaxel / Q000008:administration & dosage; D049268:Positron-Emission Tomography / Q000379:methods*; D011799:Quinazolines / Q000627:therapeutic use; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D016190:Carboplatin; D017239:Paclitaxel; D000077156:Gefitinib
keywords: Cytotoxic chemotherapy; Epidermal growth factor receptor tyrosine kinase inhibitor; Gefitinib; Molecular targeted therapy; Non–small-cell lung cancer